News Circassia leads UK biotech funding success Three separate fund-raising rounds - headed by Circassia's £275 million placing and open offer - give a further indication of the revival in the
News FDA clears Sanofi's Type 3 Gaucher therapy Infilbray Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.